Article

Bausch & Lomb signs agreement

Bausch & Lomb has entered into a collaborative research agreement with Galapagos NV, a drug discovery company based in Mechelen, Belgium, giving B&L the exclusive option to license select Galapagos compounds as development candidates for therapeutic uses in ophthalmic diseases.

Rochester, NY-Bausch & Lomb (B&L) has entered into a collaborative research agreement with Galapagos NV, a drug discovery company based in Mechelen, Belgium, giving B&L the exclusive option to license select Galapagos compounds as development candidates for therapeutic uses in ophthalmic diseases.

"The small-molecule compounds under evaluation have very attractive in vitro and in vivo profiles," said Praveen Tyle, PhD, B&L chief scientific officer. "Our intent is to develop these compounds as unique therapies, tapping our research expertise in ophthalmic diseases."

Onno van de Stolpe, chief executive officer of Galapagos, said, "Our collaboration with B&L gives us the opportunity to leverage select compounds in a therapeutic area that we would not otherwise pursue."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.